Drug Discovery@nature.com 13 January 2012

TABLE OF CONTENTS 13 January 2012 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   News Top Incyte comes of age with JAK inhibitor approval doi:10.1038/nbt0112-3 Incyte's first drug to market, Jakafi (ruxolitinib), is one that validates a novel mechanism of action in cancer - blocking the Janus-kinases JAK1 and JAK2. Full Text Eylea approval transforms Regeneron doi:10.1038/nbt0112-4 Regeneron's launch of Eylea (aflibercept) to treat wet age-related macular degeneration effectively changes the company from one dependent on partnering and licensing into a commercial organization. Full Text Rules tighten on use of antibiotics on farms doi:10.1038/481125a Clampdown aims to stop spread of drug-resistant microbes. Full Text An audience with Mark Fishman doi:10.1038/nrd3640 Mark Fishman, President of the Novartis Institutes for BioMedical Research, looks back on his past decade of heading up R&D. Full Text Analysis Top No place like inflammasome doi:10.1038/scibx.2012.1 Researchers have found that inhibiting inflammasome formation with P2X7 antagonists could help prevent heart failure following acute myocardial infarction. The findings highlight a repurposing opportunity for P2X7 antagonists that companies have in the clinic for inflammatory indications. Full Text Fresh from the Pipeline: Brentuximab vedotin doi:10.1038/nrd3629 In August 2011, brentuximab vedotin (Adcetris; Seattle Genetics), a CD30-specific antibody-drug conjugate, was approved by the US Food and Drug Administration for the treatment of patients with Hodgkin's lymphoma and patients with systemic anaplastic large cell lymphoma. Full Text From the analyst's couch: A decade of change doi:10.1038/nrd3630 Data on indicators such as the number and success rate of research and development projects illustrate trends in the pharmaceutical industry over the past decade. Full Text Research Highlights Top Vaccines: Enhancing glycan presentation increases vaccine efficacy doi:10.1038/nrd3637 By maximizing the presentation of carbohydrate epitopes to T cells, scientists have constructed a vaccine against group B streptococcus that is significantly more potent than currently available vaccines. Full Text Antiparasitic drugs: Two-pronged tactics for malaria control doi:10.1038/nrd3635 An academia–industry consortium has identified a new class of compounds that confer complete protection against parasite challenge in rodent models of malaria, as well as showing potent in vivo activity against blood-stage parasites. Full Text Epigenetics: Worth another look? doi:10.1038/nrc3187 Patients with non-small-cell lung cancer with tumours that have a specific subset of methylated genes might benefit from combined treatment with a low-dose DNA methyltransferase inhibitor and a histone deacetylase inhibitor. Full Text Research & Reviews Top The pharmacological landscape and therapeutic potential of serine hydrolases doi:10.1038/nrd3620 This article outlines the current state of pharmacology for mammalian serine hydrolases, including marketed drugs, compounds that are under clinical investigation and selective inhibitors emerging from academic probe development efforts. Full Text Cancer immunotherapy comes of age doi:10.1038/nature10673 Advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses, together with the advent of targeted therapies, suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients. Full Text Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons doi:10.1038/nature10726 Findings from a recent Nature study suggest a therapeutic strategy for reactivating the functional but dormant allele of Ube3a in patients with Angelman syndrome using topoisomerase inhibitors. Full Text Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential doi:10.1038/nm.2582 Antibodies that bind and inhibit activated matrix metalloproteinases 2 and 9 in a manner analogous to the mechanism of action of tissue inhibitors of metalloproteinases are therapeutically effective in mouse models of inflammatory bowel disease. Full Text Drug Discovery JOBS of the week Head of Structural Biology / Crystallography H3 Biomedicine MRes in Drug Discovery and Development Imperial College London Scientist, Small Molecule Discovery Toxicology (Safety Assessment) Genentech (Senior) Principal Scientist Eisai Ltd Research Investigator in Oncology BeiGene Inc. More Science jobs from Drug Discovery EVENT Advances and Progress in Drug Design 21.-22.01.12 London, UK More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.